Triple negative breast cancer (TNBC) is diagnosed in 15–20% of all breast cancer patients and is defined by the absence of ER, PR, and HER2 expression (Fragomeni et al. 2018; Foulkes et al. 2010). This evidence concerns the gene ERBB2 and breast cancer.